PMID- 31728681
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20221207
IS  - 1436-6215 (Electronic)
IS  - 1436-6207 (Linking)
VI  - 59
IP  - 7
DP  - 2020 Oct
TI  - Prebiotic supplementation modulates advanced glycation end-products (AGEs), 
      soluble receptor for AGEs (sRAGE), and cardiometabolic risk factors through 
      improving metabolic endotoxemia: a randomized-controlled clinical trial.
PG  - 3009-3021
LID - 10.1007/s00394-019-02140-z [doi]
AB  - PURPOSE: The oxidative stress plays a key role in the initiation, propagation, 
      and development of the complications of type 2 diabetes mellitus (T2DM). This 
      trial aimed to evaluate the effects of resistant dextrin as a prebiotic on the 
      cardiometabolic risk factors and the status of oxidative stress in patients with 
      T2DM. METHODS: Sixty-five female subjects with T2DM were assigned to either the 
      intervention (n = 33) or control (n = 32) groups receiving 10 g/day of resistant 
      dextrin or placebo, respectively, for 8 weeks. Fasting blood samples were 
      collected at baseline and post-intervention to determine the serum levels of 
      glycemic indices, lipid profile, atherogenic indices, and soluble receptor for 
      AGEs (sRAGE), carboxymethyl lysine (CML), pentosidine, malondialdehyde (MDA), 
      8-iso-prostaglandin F2alpha (8-iso-PGF2alpha), total antioxidant capacity (TAC), 
      antioxidant enzymes activity, and uric acid. Data were analyzed using SPSS 
      software 17. Paired, unpaired Student's t tests, and analysis of covariance were 
      used to compare the quantitative variables. RESULTS: Resistant dextrin caused a 
      significant decrease in FPG (- 17.43 mg/dl, 9.80%), TG (- 40.25 mg/dl, 23.01%), 
      TC/HDL (- 0.80, 21.87%), LDL-c/HDL-c (- 0.80, 17.85%), Atherogenic index (- 0.40, 
      15.80%), LPS (- 6.5 EU/ml, 23.40%) and hs-CRP (- 8.02 ng/ml, 54.00%), MDA 
      (- 1.21 nmol/mL, 25.58%), CML (- 93.40 ng/ml, 26.30%), 8-iso-PGF2alpha (- 4.65 pg/ml, 
      15.00%), and a significant increase in TAC (0.33 mmol/L, 36.25%) and s-RAGE 
      (2.10 ng/ml, 28.90%) in the intervention group compared with the control group. 
      No significant changes were observed in glycosylated hemoglobin, total 
      cholesterol, LDL-c, HDL-c, superoxide dismutase, glutathione peroxidase and 
      catalase, pentosidine, and uric acid in the intervention group compared with the 
      control group. CONCLUSIONS: Supplementation with resistant dextrin may improve 
      the advanced glycation end-products, sRAGE, and cardiometabolic risk factors in 
      women with type 2 diabetes mellitus.
FAU - Farhangi, Mahdieh Abbasalizad
AU  - Farhangi MA
AD  - Drug Applied Research Center, Nutrition Research Center, Faculty of Nutrition, 
      Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Dehghan, Parvin
AU  - Dehghan P
AD  - Nutrition Research Center, Immunology Research Center, Faculty of Nutrition, 
      Tabriz University of Medical Sciences, Tabriz, 5166614711, Iran. 
      dehghan.nut@gmail.com.
FAU - Namazi, Nazli
AU  - Namazi N
AD  - Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences 
      Institute, Tehran University of Medical Sciences, Tehran, Iran.
LA  - eng
GR  - 11/University of Tabriz/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20191114
PL  - Germany
TA  - Eur J Nutr
JT  - European journal of nutrition
JID - 100888704
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Prebiotics)
RN  - 0 (Receptor for Advanced Glycation End Products)
SB  - IM
MH  - Cardiometabolic Risk Factors
MH  - *Diabetes Mellitus, Type 2
MH  - *Endotoxemia
MH  - Female
MH  - Glycated Hemoglobin
MH  - Glycation End Products, Advanced
MH  - Humans
MH  - Prebiotics
MH  - Receptor for Advanced Glycation End Products
OTO - NOTNLM
OT  - Advanced glycation end-products
OT  - Blood pressure
OT  - Cardiovascular diseases
OT  - Lipid profile
OT  - Prebiotic
OT  - Resistant dextrin
OT  - sRAGE
EDAT- 2019/11/16 06:00
MHDA- 2021/06/24 06:00
CRDT- 2019/11/16 06:00
PHST- 2019/04/27 00:00 [received]
PHST- 2019/11/04 00:00 [accepted]
PHST- 2019/11/16 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2019/11/16 06:00 [entrez]
AID - 10.1007/s00394-019-02140-z [pii]
AID - 10.1007/s00394-019-02140-z [doi]
PST - ppublish
SO  - Eur J Nutr. 2020 Oct;59(7):3009-3021. doi: 10.1007/s00394-019-02140-z. Epub 2019 
      Nov 14.